个人简历

1976.05-，北京协和医学院医药生物技术研究所，医学博士。新乡医学院医学检验学院院长，硕士生导师。主持国家自然科学基金面上项目2项，河南高校创新人才项目1项，河南省教育厅青年骨干教师项目1项。在Clinic Cancer Research、Oncotarget等SCI期刊上发表论文11篇，中文核心期刊6篇，为Current drug metabolism、Diagnostic Pathology等期刊审稿人。为国家“十二五”《临床免疫学检验》数字教材编委，《临床免疫学检验技术实验指导》编委，全国普通高等教育医学检验技术类系列教材《临床免疫检验学》副主编，译著《肝脏免疫学：基础与临床》编委。
近年来获得的成果奖
朱小飞6/7，成人T淋巴细胞白血病相关基因的研究与应用，河南省人民政府省级，三等奖，2014，第六
朱小飞4/8，旨在增强力达霉素抗肿瘤活性的靶向性融合蛋白的构建及活性检测，河南省人民政府省级，三等奖，2019，第四

研究领域

肿瘤免疫学与感染免疫学，主要从事肿瘤靶向药物、HTLV-1病毒与宿主的免疫调控机制、代谢性疾病免疫异常的分子机制研究

近期论文

Guo X, Yin X, Zhu W, Pan Y, Wang H, Liang Y, Zhu X*. The preconditioning of Busulfan promotes efficiency of human CD133+ cell engraftment in NOD Shi-SCID IL2Rγc null (NOG) mice via intra-bone marrow injection. Cell Transplant. 2019, 963689719842162.
Zhu X#*, Yang J, Zhu W, Yin X, Yang B, Wei Y, Guo X. Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy. Int J Mol Sci. 2018 Dec 6;19(12)
Guo XF, Li SS, Zhu XF, Dou QH, Liu D.Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.Cancer Chemother Pharmacol. 2018 Sep;82(3):383-394
Zhu X#*, Yue H, Guo X, Yang J, Liu J, Liu J, Wang R, Zhu W. The Preconditioning of Berberine Suppresses Hydrogen Peroxide-Induced Premature Senescence via Regulation of Sirtuin 1. Oxid Med Cell Longev. 2017,2391820.
He J, Mai J, Li Y, Chen L, Xu H, Zhu X*, Pan Q. miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2. Oncol Rep. 2017 May;37(5):2672-2678.
Guo XF, Zhu XF, Cao HY, Zhong GS, Li L, Deng BG, Chen P, Wang PZ, Miao QF, Zhen YS. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. Oncotarget. 2017 Apr 18;8(16):27286-27299.
Cao HY, Guo XF, Zhu XF, Li SS, Zhen YS. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. Oncol Rep. 2017 Jun;37(6):3329-3340.
Guo XF#, Zhu XF#, Yang WC 3, Zhang SH 4, ZhenYS 4. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows highefficacy against esophageal cancer. PLoS One. 2014 Mar 24;9(3):e92986.
Zhu X#*, Guo X, Mao G, GaoZ, Wang H, He Q, Li D. Hepatoprotection of berberine against hydrogenperoxide-induced apoptosis by upregulation of Sirtuin 1. Phytother Res. 2013, 7(3):417-21.
Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncol Rep. 2012 May; 27(5):1639-45.
Guo XF#, Zhu XF#, Shang Y, Zhang SH, Zhen YS. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res. 2010 Apr 1; 16(7):2085-94